In terms of MPS here what was stated in currently Qtrly:
"Paradigm has now completed clinical studies for MPS I and VI with strong data sets and meaningful endpoints identified to progress the clinical development of iPPS as an adjunctive therapy with a commercial partner"
Previous Qtrly:
"Paradigm is actively seeking to partner this clinical asset to progress iPPS for treatment of MPS toward commercialisation."
In terms of MPS here what was stated in currently...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 33599 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 65498 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |